Expanding the Genotype of Sjögren-Larsson Syndrome: A New Case Due to Two Novel Mutations.

However, some of these patients develop SCARs related to sorafenib, such as Drug Reaction with Eosynophilia and Systemic Symptoms (DRESS), SJS or AGEP.5,6,8,9 To our knowledge, only 2 more cases of sorafenib-induced acute exanthematous pustulosis have been published, being one of them an acute localized exanthematous pustulosis (ALEP) and the other one a complete AGEP.5,6 The main features of these cases are presented in Table 1. Interestingly, all the three cases occurred in women who were under treatment with sorafenib due to unresectable hepatocarcinoma. Cases of AGEP have also been reported associated with other multikinase inhibitors such as imatinib.10 Therefore; we believe that the association between kinase-inhibitors and AGEP might be an under-reported entity with an increasing incidence due to the appearance of new drugs of this nature. In conclusion, we report a new case of sorafenib-induced AGEP. We should be aware of this cutaneous side effect of sorafenib and other multikinase inhibitors, given that drug discontinuation is the key point on AGEP treatment.